60. Highest Genomic Replikin Counts Found in Antibiotic-Resistant Bacteria March 14, 2013
Replikins Synthetic Vaccines Against Antibiotic-Resistant Gonococcus,
Tuberculosis, Staphylococcus, Streptococcus, Klebsiella KPC, and Cl. Difficile
OTTAWA, Ontario, March 14, 2013 /PRNewswire/ -- A group of lethal bacteria are
of increasing concern worldwide because they are becoming resistant to many or
all of the antibiotics previously effective against them (1). Bioradar UK Ltd.
announced today in Ottawa, Canada that it has discovered that the
concentration of genomic Replikins is markedly increased in antibiotic-resistant
bacteria. This finding is permitting a new approach to the problem of antibiotic
The specific change in the Replikins genomic structure of the Replikins provides
a novel target: proprietary Replikins Synthetic Vaccines like those found
effective against H5N1 influenza in poultry and lethal Taura Syndrome virus in
shrimp, have been formulated, and which are now available for testing against
lethal antibiotic-resistant Gonococcus, Tuberculosis, Staphylococcus,
Streptococcus, Klebsiella KPC, and Cl. Difficile.
For example, in Replikin Analysis of antibiotic-sensitive-Gonococcus, in all
5,110 genomic sequences on Pubmed, the percent of the gonococcus population with
ReplikinCounts above 4.0 is only 3%; but in antibiotic-resistant-Gonococcus, the
percent in the gonococcus genome with ReplikinCounts greater than 4.0 increased
to 95% in tetracycline-resistant Gonococcus (Figure).
In Cl. Difficile, in sequences from 86,581 specimens, the percent of
ReplikinCounts greater than 4.0 was found to increase from approximately 30% in
the year 2000 to 45.6% in 2007 and has remained at that level to 2012. Similar
data were obtained in Staphylococcus, with 86% above a Count of 4.0 in 2006, and
in Streptococcus, with 65% above a Count of 4.0 in 2009 (2).
When an association of genomic Replikins was first observed in Tuberculosis (3),
there was no reason to assume that this was a general genomic structural
property of resistance in bacteria. However upon Replikins Analyses of 123,704
genomic sequences from several pathogenic bacteria published in Pubmed, the
unexpected discovery was made that when bacterial resistance develops, for
example in all six of the above named bacteria of concern, there is a marked
increase in the genomic ReplikinCounts (number of genomic Replikins per 100
amino acids) (p<0.001). ReplikinCounts of 0.1 to 4.0 were found in
antibiotic-sensitive bacteria; antibiotic-resistant bacteria isolates had
ReplikinCounts greater than 4.0, which ranged from 4.1 to 50. Thus as the
resistance to antibiotics of that bacterial population increased, the percent of
ReplikinCounts in that bacterial population increased.
As new Replikins are added to or disappear from the genome during bacterial
evolution, certain individual Replikins remain conserved for decades, making
long-acting vaccines possible (3,4). This shared genomic structural property
shared by different antibiotic-resistant bacterial strains presents a new
platform in bacterial genomic structure for specific early diagnosis, vaccines,
and therapies. Effective Replikins vaccines have been synthesized more cheaply
than the cost of biological vaccines (10 cents vs 11 dollars), and in 7 days
rather than 8 months, and by solid phase synthesis in virtually unlimited
amounts, rather than only approximately 1.25 billion doses in 8 months as in the
2009 H1N1 pandemic; lacking the potential for side effects due to biological
contaminants, and shipped freeze-dried without refrigeration.
Another consequence of this finding in the genomes of infectious diseases is the
ability for the first time to predict outbreaks in advance, providing time to
respond well in advance of the outbreak. Before this work on bacteria, earlier
studies by our companies on viruses, including influenza, found that when the
virus genomes contained increasing concentrations of Replikins, outbreaks of
these specific viruses, and the geographic sites of these outbreaks, were
predicted one to two years in advance of the outbreak. Twelve out of twelve such
correct predictions, based on ReplikinCounts alone, have been made and most
published in prospective trials in the past 9 years, including Replikins' 2008
prediction of the coming 2009 H1N1 influenza pandemic (3,4).
Retrospectively, the prediction by ReplikinCounts of outbreaks also was found in
all influenza pandemics and major outbreaks in the past century (3,4). The
companies' resulting H5N1 vaccine (ReplikinsSyntheticTrans-FluTMVaccine), has
been successful in poultry in blocking virus entry, replication and excretion,
and Replikins Taura Syndrome Virus Vaccine has protected 91% of shrimp against
this fatal virus. Both vaccines were produced in 7 days and shipped freeze-dried
For licenses to test, distribute and market these new Replikins diagnostics,
vaccines and therapies against antibiotic-resistant bacteria, please
email Samuel Bogoch or call 646-320-5910.
- Cressey, Daniel..Nature News Blog, 11 Mar 2013
- Bogoch,S. and Bogoch ES. Killer Replikins, in the Genomes of Lethal Viruses, Antibiotic-Resistant Bacteria, Malaria and Cancer. In press 2013.
- Bogoch S. and Bogoch ES. Nature Precedings. Eight publications, 2011-2012.